A Treat-and-Extend Regimen of Intravitreal Brolucizumab for Exudative Age-Related Macular Degeneration Refractory to Aflibercept: A 12-Month Result

被引:7
作者
Kikushima, Wataru [1 ]
Sakurada, Yoichi [1 ]
Fukuda, Yoshiko [1 ]
Matsubara, Mio [1 ]
Kotoda, Yumi [1 ]
Sugiyama, Atsushi [1 ]
Kashiwagi, Kenji [1 ]
机构
[1] Univ Yamanashi, Fac Med, Dept Ophthalmol, Yamanashi 4093898, Japan
关键词
age-related macular degeneration; polypoidal choroidal vasculopathy; intravitreal brolucizumab injection; treat-and-extend; switching; ENDOTHELIAL GROWTH-FACTOR; SUBFOVEAL CHOROIDAL THICKNESS; PHOTODYNAMIC THERAPY; PREVALENCE; RANIBIZUMAB; MACULOPATHY; INJECTION;
D O I
10.3390/ph16040562
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
We aimed to investigate whether a treat-and-extend regimen of intravitreal brolucizumab (6.0 mg/0.05 mL) is effective for eyes with exudative age-related macular degeneration (AMD) refractory to aflibercept for 12 months. Sixty eyes from 56 patients receiving brolucizumab for exudative AMD refractory to aflibercept were included. Patients received a mean of 30.1 aflibercept administrations for a mean 67.9-month follow-up. All patients exhibited exudation on optical coherence tomography (OCT) despite regular 4-8 weeks of aflibercept administration. Visit 1 was scheduled at the same interval from the last aflibercept injection to the baseline. The treatment interval was extended or shortened by 1-2 weeks depending on the presence or absence of exudation on OCT. After switching to brolucizumab, the follow-up interval significantly extended at 12 months (before switching: 7.6 +/- 3.8 weeks vs. at 12 months: 12.1 +/- 6.2 weeks, p = 1.3 x 10(-7)). Forty-three percent of the eyes achieved a dry macula at 12 months after switching. However, the best-corrected visual acuity did not improve at any visit. Morphologically, the central retinal thickness and subfoveal choroidal thickness significantly decreased from baseline at 12 months (p = 3.6 x 10(-3) and 1.0 x 10(-3), respectively). Switching to brolucizumab can be considered to extend the treatment interval in eyes with exudative AMD refractory to aflibercept.
引用
收藏
页数:15
相关论文
共 70 条
  • [1] First Year Real Life Experience With Intravitreal Brolucizumab for Treatment of Refractory Neovascular Age-Related Macular Degeneration
    Abdin, Alaa Din
    Aljundi, Wissam
    El Jawhari, Khalil
    Suffo, Shady
    Weinstein, Isabel
    Seitz, Berthold
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [2] SHORT-TERM OUTCOMES AFTER INTERIM TREATMENT WITH BROLUCIZUMAB A Retrospective Case Series of a Single Center Experience
    Awh, Caroline C.
    Davis, Emily C.
    Thomas, Mridul K.
    Thomas, Akshay S.
    [J]. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2022, 42 (05): : 899 - 905
  • [3] Efficacy and safety of brolucizumab in age-related macular degeneration: A systematic review of real-world studies
    Baumal, Caroline R.
    Sorensen, Torben Lykke
    Karcher, Helene
    Freitas, Rita L.
    Becher, Anja
    Balez, Sebastien
    Clemens, Andreas
    Singer, Michael
    Kodjikian, Laurent
    [J]. ACTA OPHTHALMOLOGICA, 2023, 101 (02) : 123 - 139
  • [4] Expert Opinion on Management of Intraocular Inflammation, Retinal Vasculitis, and Vascular Occlusion after Brolucizumab Treatment
    Baumal, Caroline R.
    Bodaghi, Bahram
    Singer, Michael
    Tanzer, David J.
    Seres, Andras
    Joshi, Mayur R.
    Feltgen, Nicolas
    Gale, Richard
    [J]. OPHTHALMOLOGY RETINA, 2021, 5 (06): : 519 - 527
  • [5] Retinal Vasculitis and Intraocular Inflammation after Intravitreal Injection of Brolucizumab
    Baumal, Caroline R.
    Spaide, Richard F.
    Vajzovic, Lejla
    Freund, K. Bailey
    Walter, Scott D.
    John, Vishak
    Rich, Ryan
    Chaudhry, Nauman
    Lakhanpal, Rohit R.
    Oellers, Patrick R.
    Leveque, Thellea K.
    Rutledge, Bryan K.
    Chittum, Mark
    Bacci, Tommaso
    Enriquez, Ana Bety
    Sund, Newman J.
    Subong, Eric N. P.
    Albini, Thomas A.
    [J]. OPHTHALMOLOGY, 2020, 127 (10) : 1345 - 1359
  • [6] Bayés M, 2004, METHOD FIND EXP CLIN, V26, P473
  • [7] Initial Pro Re Nata Brolucizumab for Exudative AMD: The PROBE Study
    Bilgic, Alper
    Kodjikian, Laurent
    Srivastava, Samaresh
    Dwivedi, Shyamal
    Banker, Alay S.
    Abukashabah, Amro
    Sudhalkar, Aditya
    Mathis, Thibaud
    [J]. JOURNAL OF CLINICAL MEDICINE, 2021, 10 (18)
  • [8] Real-World Experience with Brolucizumab in Wet Age-Related Macular Degeneration: The REBA Study
    Bilgic, Alper
    Kodjikian, Laurent
    March de Ribot, Francesc
    Vasavada, Vaishali
    Gonzalez-Cortes, Jesus H.
    Abukashabah, Amro
    Sudhalkar, Aditya
    Mathis, Thibaud
    [J]. JOURNAL OF CLINICAL MEDICINE, 2021, 10 (13)
  • [9] Brolucizumab for pre-treated patients with choroidal neovascularization and signs of tachyphylaxis to aflibercept and bevacizumab
    Boltz, Agnes
    Radunsky, Katharina
    Weingessel, Birgit
    Vecsei-Marlovits, Veronika Pia
    [J]. GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2022, 260 (08) : 2561 - 2566
  • [10] KESTREL and KITE: 52-Week Results From Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular Edema
    Brown, David
    Emanuelli, Andres
    Bandello, Francesco
    Barranco, Jose Juan Escobar
    Figueira, Joao
    Souied, Eric
    Wolf, Sebastian
    Gupta, Vishali
    Ngah, Nor Fariza
    Liew, Gerald
    Tuli, Raman
    Tadayoni, Ramin
    Dhoot, Dilsher
    Wang, Lixin
    Bouillaud, Emmanuel
    Wang, Ying
    Kovacic, Lidija
    Guerard, Nicolas
    Garweg, Justus G.
    [J]. AMERICAN JOURNAL OF OPHTHALMOLOGY, 2022, 238 : 157 - 172